A B S T R A C T We measured the effects of seven consecutive daily infusions of a-ketoisocaproate (the a-keto analogue of leucine) or leucine itself on urinary urea and total nitrogen excretion during fasting. Two study protocols were undertaken. In protocol I, subjects underwent three separate 14-d fasts: one during which 34 mmol/d of leucine were infused on days 1-7; a second during which 34 mmol/d of a-ketoisocaproate were infused on days 1-7; and a third control fast during which no infusions were given. Infusions of a-ketoisocaproate significantly reduced daily urine urea nitrogen excretion compared with both the control fasts and the fasts in which leucine was infused (P < 0.001). This nitrogen-sparing effect of a-ketoisocaproate persisted during days 8-14 even though no further infrisions were given. Daily urinary urea nitrogen excretion during fasts when leucine was administered did not differ from values observed during control fasts. In protocol II, subjects were starved on two occasions for 14 d. During one fast, infusions of 11 mmol/d ofa-ketoisocaproate were given on days 1-7; during the control fast, no infusions were given. Daily urine urea nitrogen excretion was lower (P < 0.001) on days 1-7 and also on days 8-14 ofthe fast during which a-ketoisocaproate was given.
INTRODUCTION
In in vitro experiments, branched-chain amiino acids, particularly leucine, have been shown to stimulate protein synthesis in skeletal muscle (1, 2) . In addition, leucine has been reported to diminish the rate of muscle protein degradation of the isolated rat hemidiaphragm (1) , an effect which is apparently attributable to its a-keto analogue, a-ketoisocaproic acid. In man, infusion of valine, isoleucine, and leucine has been shown to reduce nitrogen wasting during the immediate postoperative period (3) . Finally, it has been reported recently that infusion of leucine improved nitrogen balance of fasting individuals in addition to decreasing glucose turnover and the concentrations ofcirculating plasma amino acids (4) . Thus, leucine and/or its metabolic products appear to have an important regulatory role in protein metabolism of man, as well as the experimental animal.
In fasting human subjects, infusion of a combination of the a-keto analogues of valine, leucine, and isoleucine decreases urea nitrogen excretion and improves nitrogen balance (5) . Comparable experiments with the three branched-chain amino acids themselves have not been carried out. To determine whether leucine, adminiistered as such or as its a-keto analogue is more effective in promoting nitrogen sparing during starvation, we have compared the effects of equimolar infrision of leucine and a-ketoisocaproate on urea nitrogen and total nitrogen excretion of fasting subjects. To determine whether the nitrogen-sparing effect of infusing the a-keto analogues of leucine, valine, and isoleucine in the previous study (5) was attributable entirely to the leucine analogue, we also examined the effects on nitrogen excretion of infusing 11 mmol/d of a-ketoisocaproate, the quantity administered during the previous study. METHODS Two male and nine female volunteers participated in one or both of two study protocols. Informed consent was obtained for starvation protocols and for infusions of leucine or a-ketoisocaproate. The average age of the subjects was 37 yr (range 20-61). Their average weight upon entering the first study was 135 kg (range 74.5-200 kg) and their average height was 163.8 cm. They averaged 222% of ideal body weight (based on 1959 Metropolitan Life Insurance Company Tables; Metropolitan Life Insurance Company, New York). No patient had a fasting blood glucose greater than 120 mg/dl or evidence of abnormal cardiac, thyroid, hepatic, or renal function. During the 4 d before beginning a study, the subjects ate diets consisting of at least 2,500 kcal/d containing a minimum of 300 g/d of carbohydrate and 75 g/d of protein. They were taking no drugs with the exception of one female subject who took 40 mg/d of megesterol acetate throughout her studies.
In protocol I, five females and one male each underwent three separate fasts, each fast lasting 14 d. During the first 7 d'of one fast, they received a daily intravenous infusion of 34 mmol of sodium a-ketoisocaproate in 250 ml water over a 2-3 h period. During the first 7 d of a second fast, they were infused with 34 mmol of leucine contained in 500 ml of 0.45% NaCl over a 3-h period. During the third fast, which served as a control, they received no infusions.
In protocol II, four females and two males each fasted for two 14-d periods. During the first 7 d of one fast, they received a daily intravenous infusion of 11 mmol of sodium a-ketoisocaproate in 150 ml of water administered over a 2-h period. During the other fast, no infusions were given (control study).
In each of the two protocols, 4 wk or more separated each fast, and the sequence of the study, with respect to the infusions and the control fast, was varied.
Blood sampling. For determination ofvarious metabolites, venous blood was drawn without stasis just before infusion on the 1st and 7th d and again 1 h after completion of the infusion. Blood was also drawn at completion of the fast on the morning of day 15. During the control fasts, blood was drawn on the morning of the 7th and 15th d.
Analytical methods. Supernates prepared from sulfosalicylic acid-LiOH (pH 1.80) and precipitates of plasma were frozen until analyzed for amino acid concentrations using a Beckman 119 amino acid analyzer (Beckman Instruments, Inc., Fullerton, Calif.). Supernates of perchloric acid precipitates of whole blood were prepared immediately and frozen until analyzed for glutamine, acetoacetate, and f8-hydroxybutyrate concentrations (5) . Ketone body concentrations were measured within 1 wk of sampling. When stored at -20'C for 7 d, recovery rates for acetoacetate and f8-hydroxybutyrate were 98.4+5.3 and 98.0+3.7%, respectively. For measurement of plasma immunoreactive insulin, 9 vol of plasma were promptly diluted with 1 vol of Trasylol (5,000 U/ml; FBA Pharmaceuticals, Inc., New York) and frozen until assayed. Serum urea nitrogen was also measured (5) .
Throughout the study, daily 24-h urine specimens were collected in bottles containing thymol as a preservative, refrigerated at 4°C during the collection period, and then frozen until analyzed. Urea nitrogen, ammonium, creatinine, uric acid, sodium, and potassium concentrations of each 24-h urine collections were measured as previously described (5) . Urinary total nitrogen was calculated as the sum of urea, creatinine, uric acid, and ammonium nitrogen (5) .
Stools were passed infrequently during the fasts, and nitrogen losses by this route were not measured. Statistical analyses were performed using three-way analysis of variance and the paired t test (6) .
RESULTS
Nitrogen excretion. Before beginning the fasts, the average daily urea nitrogen excretion of subjects, who subsequently received 11 or 34 mmol of a-ketoisocaproate, 34 mmol of leucine, or underwent a control fast without infusions was not significantly different.
In Table I are shown mean values of the daily urea nitrogen excretion for days 1-7 and 8-14 of the three fasts ofprotocol I. Tables II-V give the individual data: the control fast without infusions and the two fasts when either 34 mmol/d of a-ketoisocaproate or 34 mmol/d of leucine were infused on days 1-7. When these results were analyzed by the technique of analysis of variance, infusions of a-ketoisocaproate were associated with significantly lower urea nitrogen excretion compared with the control fast, both for the initial 7-d period ofa-ketoisocaproate infusion and for the next 7 d in which no infusions were given. Compared with the fast during which leucine was infused, a-ketoisocaproate also resulted in a significantly lower rate of urea nitrogen excretion on days 1-7 and 8-14. The difference is also present if the amount of nitrogen contained in the leucine infusions is subtracted from the amount of urea nitrogen excretion. In contrast with the nitrogen-sparing effect of a-ketoisocaproate, urinary urea nitrogen excretion rates on days 1-7 and 8-14 during the leucine infusion fast were not significantly different from those of the control fast, even if the quantity of nitrogen contained in each leucine infusion was subtracted from the daily values for urinary urea nitrogen. * Significance determined by analysis of variance between control fasts and fasts during which a-ketoisocaproate or leucine was infused. If daily urea nitrogen excretion is reduced by subtracting nitrogen contained within leucine infusions, then mean daily urea nitrogen excretion is 6.42 g/d. This figure remains significantly higher (F = 11.62, P < 0.001) than mean daily urea nitrogen excretion during a-ketoisocaproate infusion. The average urea nitrogen excretion for each day of was lower during all 14 d of the a-ketoisocaproate the three studies is graphically displayed in Figs. 1 and study. 2. In Fig. 1 is shown a comparison of daily urinary urea Infusion of 11 mmol/d of a-ketoisocaproate on days nitrogen during the control fast and the fast when a-1-7 of a 14-d fast (protocol II) also significantly lowered ketoisocaproate was infused. Urea nitrogen excretion mean daily urine urea nitrogen excretion compared was lower during 13 of 14 d of the infusion study. with the control fast without infusions. Again, the lower Similar results were found when the study with leucine urea nitrogen excretion was observed during the week infusions was compared with the study with a-ketoof infusions and for the next week when no infusions isocaproate infusions (Fig. 2 ). Urea nitrogen excretion were administered (Table VI) . Urea nitrogen excretion values for each day of the stuidies ofprotocol II are graphically displayed in Fig. 3 . Compared with a control fast, urea nitrogen excretion was lower for all 14 d of the infusion study.
Total urinary nitrogen excretion was estimated as the stum of daily excretion of creatinine, uric acid, ammonium, and urea nitrogen. The sum of creatinine, uric acid, and ammonium did not differ significantly between the three fasts of protocol I and the two fasts of protocol II when the data were analyzed by analysis of varianice. Thus, the differences found in estimated total urinary nitrogen excretion were a result of urea nitrogen exeretion. The nitrogen-sparing effects of infusing 11 or 34 mm-ol of a-ketoisocaproate were similar, and averaged approximately 1 g/d over the entire 14-d study.
Plasmtia ami)10o acids. The changes in plasma amino acid concentrations during control fasts of protocols I and II were similar to those described by Felig et al. (7) .
Plasma amino acid concentrations of the six patients measured during protocol I studies were compared in the following ways. (a) Plasma amino acid values measured on day 1 before the first infusion of 34 mmol of a-ketoisocaproate or 34 mmol of leucine were compared (Table VII) : there were no significant differences in any of the amino acid concentrations. (b) On days 1 and 7, the percent changes from preinfusion values of plasma amino acid concentrations measured 1 h after infusion of 34 mmol of a-ketoisocaproate and 34 mmol of leucine were compared (Table VII) : 1 h after infusion of 34 mmol of a-ketoisocaproate, the average plasma leucine concentration increased 61 and 69% on days 1 and 7, respectively. On days 1 and 7, infusion of 34 mmol of a-ketoisocaproate as well as infusion of 34 mmol of leucine significantly reduced the total concentration of plasma amino acids (Table VII) . The decrease in total amino acid concentration 1 h after infusion of 34 mmol of leucine and 34 mmol of a-ketoisocaproate was not different on day 1 (-12% leucine, -16% a-ketoisocaproate) or on day 7 (-6% leucine, -9% a-ketoisocaproate). Significant decreases in many individual amino acid concentrations were observed after infusion of a-ketoisocaproate or leucine (Table  VII) . (c) Preinfusion plasma amino acid concentrations on day 7 of studies in which a-ketoisocaproate or leucine was administered were compared with each other. The same comparisons were made from values obtained on the morning of the last study day. When a-ketoisocaproate and leucine infusions were compared, there were no significant differences in plasma amino acid concentrations on day 7 or on the morning after the last study day, except for a lower plasma gly- cine concentration (P < 0.025) on day 7 of the study in which a-ketoisocaproate was infused. (d) Values obtained before infusion of a-ketoisocaproate or leucine on day 7 and values obtained on day 15 of these studies were compared with values obtained on the morning of days 7 and 15 of the control fast. Compared with values obtained on day 7 of the control study, on the morning of the last day of infusion of 34 mmol of a-ketoisocaproate plasma threonine was lower (-34±12 ,uM, P < 0.05), and plasma alloisoleucine was higher (+17 ±4 AM, P < 0.025). Comparison of plasma amino acid concentrations on day 15 of control and infusion fasts showed few differences. a-Ketoisocaproate infusion was associated with a decrease in cystine (-21±7 ,uM) and lysine (-24±8 ,tM), P < 0.05, compared to control. Leucine inftision was associated with a decrease in serine (-31±11 ,uM) and cystine (-18±6 uM) concentrations, P < 0.05 compared with control. Comparison of plasma amino acid concentrations during protocol II studies was also carried out in several ways: Plasma amino acid values prior to infusion (day 1 and day 7) were compared with values obtained 1 h after infusion of 11 mmol of a-ketoisocaproate. a-Ketoisocaproate resulted in a 9 and 7% decrease in total plasma amino acids on days 1 and 7, respectively.
1 h after infusion of 11 mmol a-ketoisocaproate, plasma leucine concentration increased on days 1 and 7 by 32 and 21% respectively, whereas the concentrations of a number of individual amino acids decreased (Table VIII) . Plasma amino acid concentrations obtained on day 7 and the last day of the control fast were compared with values obtained before infusion of a-ketoisocaproate (day 7) and 1 wk after infusions were discontinued. On day 7, the infusions ofa-ketoisocapro- Insulin and pH. Plasma insulin concentration was not significantly increased 1 h after infusion of 11 or 34 mmol of a-ketoisocaproate or 34 mmol of leucine. The mean plasma insulin concentration on days 7 and 15 of control fasts (13±3 and 18±6 U/ml) was not significantly different from that measured on days 7 and 15 before the infusions in protocols I and II.
There were no significant changes in venous pH or calculated plasma bicarbonate concentration measured 1 h after infusion of a-ketoisocaproate or leucine. Similarly, there were no differences in these acid-base parameters when values from days 7 and 15 of infusion fasts were compared with values obtained during the respective control fasts (protocols I and II).
Urine volume, sodium excretion, and weight loss. There were no significant differences in daily urine volume or cumulative sodium excretion between the infusion fasts and control fasts of protocol I studies. There were no significant differences in mean cumulative weight loss during control (-11.2± 1.0 kg) fasts or fasts when 34 mmol a-ketoisocaproate (-12.4±1.1 kg) were infused, or when 34 mmol of leucine were infused (-12.7± 1.1 kg). 
Total measured amino acids 3,091 -272t 3,170 -169 * Glutamine measured enzymatically in whole blood. t P < 0.025. § P < 0.01. "p < 0.001. ¶ P < 0.05.
DISCUSSION
Several tissues, including skeletal muscle, gut, liver, and kidney can interconvert a-keto analogues of branched-chain amino acids and their respective amino acids (8) (9) (10) . Because of this interconversion, it is difficult to ascribe biological effects to either branchedchain amino acids or their a-keto analogues after administration of one or the other compound. In the present study, we attempted to address this problem by studying the effects of leucine and a-ketoisocaproate in the same patients. The results indicate that the effect of administration of a-ketoisocaproate in fasting subjects is different from the effects of administering leucine, even though leucine must have been metabolized to a-ketoisocaproate. We found that intravenous infusion of a-ketoisocaproate reduces urea nitrogen and calculated total nitrogen excretion of obese subjects undergoing starvation. This phenomenon was not observed when leucine was infused in the same subjects. Total urinary nitrogen excretion during infusion of leucine was insignificantly different from control values even if nitrogen contained in the infused leucine were subtracted from the amount of nitrogen excreted. It should be emphasized that these experiments were carried out in fasting obese subjects, and different results may have been obtained in fasting nonobese subjects. During the early phase of starvation, when glucose is a prime energy source, release of amino acids from skeletal muscle is increased to provide gluconeogenic substrates. Later in starvation, muscle amino acid release decreases as ketone bodies and fatty acids become the major energy source (11) . From these considerations, a likely site of the observed effects of a-ketoisocaproate on urine urea nitrogen excretion during the early phase of starvation is skeletal muscle. Furthermore, a-ketoisocaproate does not affect ureagenesis in isolated hepatocytes (12) .
After addition of leucine, alanine release from the muscle is increased, presumably as a result of transamination of pyruvate (13) . Infusion of a-ketoisocaproate decreases alanine release from the muscle, probably by diverting nitrogen from amination ofpyruvate. However, the decrease in alanine release in isolated perfused muscle is less than the increment in leucine release, at least in certain experimental models (8) . Thus, it is difficult to assign the effect of a-ketoisocaproate on urea nitrogen excretion entirely to diminished output of alanine from muscle. Furthermore, we found no differences in circulating levels of alanine when either a-ketoisocaproate or leucine was infused. Likewise, Sherwin (4) found either no change or a decrease in plasma alanine after infusion ofleucine. Thus, plasma alanine concentration may not reflect changes in the release of this amino acid from the periphery. Moreover, we cannot attribute our findings to a decrease in circulating total a-amino nitrogen, because this quantity fell by a similar amount after infusion of either leucine or a-ketoisocaproate.
Recently it was reported that during infusion of aketoisocaproate into forearm muscle of normal subjects fasted overnight, there was no detectable change in arteriovenous difference of tyrosine, phenylalanine, lysine, or total a-amino nitrogen (14) , suggesting that a-ketoisocaproate had no anabolic effect in muscle. These results might suggest that the effect of a-ketoisocaproate we have observed involves an organ other than skeletal muscle. However, the results obtained by Pozefsky and Walser (14) may not apply in the analysis of our findings. In the forearm perfusion study, subjects were fasted overnight, and the duration of the infusion was only 30 min. Furthermore, small changes in amino acid flux that would suggest changes in muscle nitrogen balance may have been obscured by errors in blood flow measurement.
As cited previously, branched-chain amino acids, and specifically leucine, increase the protein synthesis rate of isolated, incubated rat diaphragm muscle (1, 2) . Furthermore, Fulks et al. (1) have shown that leucine decreased the rate of catabolism in these muscles. Chang and Goldberg (15) reported that addition of a-ketoisocaproate to incubated skeletal muscle obtained from fasted rats reduced oxidation of pyruvate and accelerated its release from muscle, as well as release of lactate. Inasmuch as lactate and pyruvate are major substrates for gluconeogenesis during early phases of fasting (16) , possible acceleration of their cellular release by a-ketoisocaproate infusions could reduce gluconeogenesis from amino acids and thereby diminish nitrogen wasting. Recently, Tischler and Goldberg (17) showed that whereas leucine itself accelerated protein synthesis in incubated rat skeletal muscle, reduction of protein degradation rate was a property of a-ketoisocaproate, not leucine. Even though leucine is metabolized to a-ketoisocaproate, Chang and Goldberg (15) have shown that the biological effects of a-ketoisocaproate may be greater after blocking its interconversion with leucine. Thus, the nitrogen-sparing effects of aketoisocaproate may be dependent upon the rate at which this compound, or its metabolites, achieves a critical concentration within cells. Our findings contrast with those reported by Sherwin (4) , who found that total urinary nitrogen excretion of fasting subjects was reduced by infusion of leucine. He reported that nitrogen excretion was decreased on day 3 of a fast when 75 umol/min per M2 of leucine was infused over 12 h, compared with urinary nitrogen excretion on the next day. We infused approximately onethird of this amount of leucine on a daily basis and a total of about 2.5 times this much over 1 wk and observed no difference in urinary nitrogen excretion on days 1-7 or 8-14 compared with urinary nitrogen excretion during a control fasting study. In contrast, infusion of an equivalent amount of a-ketoisocaproate reduced urinary nitrogen excretion on days 1-7 and 8-14 (Table I and Figs. 1 and 2 ). Sherwin (4) also found that leucine reduced urinary nitrogen excretion after 4 wk of starvation.
Interpretation of the nitrogen balance data of Sherwin (4) is complicated for the following reasons. During the infusion on day 3, nitrogen excretion decreased by approximately the same amount as it had on day 2. During the day after the infusion, urinary nitrogen excretion increased by approximately the same amount that had previously been infused as leucine (2.6 g). On the 5th d of starvation, 2 d after leucine infusion, urinary nitrogen excretion was indistinguishable from that measured on days 2 or 4. As shown in Figs. 1 and 2 , and previously reported by Owen et al. (18) urinary nitrogen excretion on days 4 and 5 of a fast (without infusions) is lower than urinary nitrogen excretion on day 2. It mav be that the nitrogen containied in leucine infused on day 3 was excreted on the two subsequent days of fasting.
In the report by Sherwin (4), leucine infusion was not accomiipainied by a decrease in urinary creatinine or 3methylhistidine excretion, but was associated with a fall in plasmiia amino acid concentrations. This was interpreted as indicating that leucine increased net protein synthesis. In our study, infuision of an equimolar amnount of a-ketoisocaproate or leucine (protocol I) was associated with a decrease in total plasma amino acid conicenitration of approximncately the same amount. Hovever, only a-ketoisocaproacte decreased urea nitrogen excretion. Thus, it is difficult to link a fall in plasma am-ino acid concentrations associated with leucine infusions to an increase in net protein synthesis.
In a previous study with a similar experimental design, we reported that the daily infusion of a combina-tioIn of a-ketoisocaproate, a-ketoisovalerate, and a-keto-,8-methylvalerate (total 34 mmol/ld) decreased urea nitrogen and calculated total nitrogen excretion. On the basis of the present data, it is possible that this effect was attributable solely to the infused a-ketoisocaproate because 11 mmol/d ofthis analogue had a similar effect on urinary nitrogen excretion (Table VI) .
In the present study, measuired changes in plasma concentration of acetoacetate, B-hydroxybutyrate, insulin, or acid-base parameters, did not appear to explain the changes in urinary nitrogen excretion induced by a-ketoisocaproate. Sherwin et al. (19) reported that infusion of -4() g/d of 8-hydroxybutyrate into starving subjects decreased plasma alanine concentrations and urinary nitrogen excretion. It seems unlikely that the present results are related to this observation, because the potential quantity of ketones we infused as a-ketoisocaproate was much smaller. Furthermore, after aketoisocaproate infusions, blood ketones rose only 0.1 mM in the present study, whereas the observed rise during Sherwin's experiments (19) was 1.5-2.0 mM.
The results of our study show that a-ketoisocaproate spares nitrogen during a fast. Investigation of the effect of this coompound on nitrogen losses in disorders characterized by nitrogen wasting is warranted.
